Equities

Veritas In Silico Inc

130A:TYO

Veritas In Silico Inc

Actions
  • Price (JPY)1,161.00
  • Today's Change-1.00 / -0.09%
  • Shares traded33.40k
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of May 29 2024 07:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Veritas In Silico Inc is a Japan-based company primarily engaged in the pharmaceutical discovery platform business. The main business is small molecule drug discovery targeting messenger ribonucleic acid (mRNA) using the ibVIS platform, which integrates digital technology including in silico ribonucleic acid (RNA) structural analysis technology and drug discovery technology, through joint drug discovery research with pharmaceutical companies to create mRNA-targeted small molecule drugs.

  • Revenue in JPY (TTM)--
  • Net income in JPY--
  • Incorporated2016
  • Employees15.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
KAINOS Laboratories, Inc.5.06bn637.97m5.19bn144.007.510.77036.901.03152.41152.411,206.781,486.430.60533.084.55--7.646.929.969.2650.4651.8412.6210.802.43--0.122118.462.711.6012.2810.57-9.8316.36
Noile-Immune Biotech Inc311.30m-975.80m5.46bn28.00--1.04--17.80-22.56-22.567.19123.550.06580.1395.0711,118,000.00-20.62---21.29--99.55---313.45--52.74-805.650.00---49.37---192.28------
Solasia Pharma KK408.00m-1.18bn5.80bn24.00--2.90--13.75-6.96-6.962.4010.010.14322.013.0617,000,000.00-41.50-48.57-53.67-58.8351.2371.01-289.71-300.891.68-400.000.2327---43.5014.1856.36------
DNA Chip Research Inc490.46m-248.29m6.15bn36.00--8.40--12.56-39.09-39.0977.17108.270.52929.843.11---26.79-23.49-32.60-26.7013.5314.28-50.62-54.102.92-2,206.97----49.746.3331.48---15.75--
Cyfuse Biomedical KK64.79m-645.40m6.16bn21.00--2.00--95.13-82.27-82.278.26378.390.01530.520213.803,085,095.00-15.19---17.68--61.81---996.19--6.39-81.610.2126---83.68---24.32------
Chiome Bioscience Inc642.70m-1.30bn6.37bn51.00--5.18--10.17-25.56-25.5612.6022.390.33484.278.9612,602,040.00-67.53-50.50-88.83-57.3855.9657.53-201.70-224.743.46-629.880.2009--8.1926.241.84------
MEDRx Co Ltd22.57m-770.66m6.37bn22.00--3.18--295.94-20.97-20.970.612847.840.01430.004.221,025,955.00-48.80-58.15-50.27-62.23100.0095.70-3,414.38-1,526.1743.57--0.00---50.3528.6016.04---55.29--
NIPPON CHEMIPHAR CO., LTD.30.75bn-180.00m6.74bn872.00--0.30895.760.219-49.89-49.898,520.205,115.780.62682.142.70---0.36890.7482-0.52041.0825.1730.99-0.58871.131.53--0.479150.33-2.57-2.10-153.10--24.62-12.94
Carna Biosciences, Inc.1.58bn-1.03bn6.76bn67.00--1.95--4.35-60.32-60.3292.24205.190.35741.2412.6323,578,990.00-23.36-14.45-25.26-16.9589.0390.59-65.36-35.4213.18--0.0326--17.2416.5914.57---27.69--
Symbio Pharmaceuticals Ltd4.64bn-2.74bn6.84bn109.00--0.9912--1.53-66.88-66.88113.80156.380.54392.765.1442,594,130.00-32.15-19.18-35.33-23.6278.3865.84-59.12-24.3210.43--0.00---44.157.82-266.45--42.39--
OncoTherapy Science, Inc.610.12m-1.29bn6.94bn60.00--18.46--11.77-6.09-6.092.871.620.5139.087.69---108.31-55.67-182.73-63.82-29.13-1.49-211.13-247.472.07-189.930.232---46.2416.81-15.15---48.33--
Veritas In Silico Inc-100.00bn-100.00bn7.06bn15.00--3.20----------363.52------------------------40.94--0.00--101.54--123.38------
K Pharma Inc500.00m-221.98m7.73bn15.00--2.74--15.74-18.94-18.9443.04247.430.20954.49--33,333,330.00-9.30---9.83--91.00---44.40--42.60--0.00------166.34------
Wakamoto Pharmaceutical Co Ltd7.74bn108.96m8.64bn292.0079.950.724489.441.133.143.14222.97346.510.49712.092.57--0.70-2.280.8046-2.6446.5251.001.41-3.973.85--0.0083---10.65-6.35-21.19--4.93--
Kohjin Bio Co Ltd4.77bn384.98m8.77bn157.0023.922.7523.021.9776.7776.77951.17666.48----------------39.44--8.07--1.14--0.4249--0.5715---53.61------
CellSeed Inc193.68m-892.21m8.82bn35.00--4.19--45.06-29.71-29.716.4764.750.0881.637.625,533,600.00-40.53-49.69-43.83-54.5556.5863.66-460.67-428.6219.14--0.0669--50.39-28.62-11.43--80.73--
Data as of May 29 2024. Currency figures normalised to Veritas In Silico Inc's reporting currency: Japanese Yen JPY

Institutional shareholders

0.11%Per cent of shares held by top holders
HolderShares% Held
Simplex Asset Management Co., Ltd.as of 09 May 20247.30k0.11%
Data from 23 May 2024 - 23 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.